<DOC>
	<DOCNO>NCT02722304</DOCNO>
	<brief_summary>The purpose study conduct pilot study evaluate safety efficacy weekly administration Alpha1-Proteinase Inhibitor ( A1PI ) augmentation therapy subject A1PI deficiency Chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Stage 1 Study ARALAST NP GLASSIA A1PI</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . ≥18 year age time screen 2 . Endogenous plasma Alpha1Proteinase Inhibitor ( A1PI ) level &lt; 8 μM time Screening period treatmentnaïve participant , follow 4weeks minimum washout previous augmentation therapy treatmentexperienced participant . The screen plasma A1PI level may repeat participant obtains exclusionary value suspect due inadequate washout A1PI ) . 3 . Participant document A1PI genotype Pi*Z/Z , Pi*Z/Null , Pi*Malton/Z , Pi*Null/Null , rare genotype ( except PI*MS , PI*MZ , PI*SZ ) . 4 . Clinically evident mildmoderate chronic obstructive pulmonary disease ( COPD ) ( accord GOLD criterion diagnosis ) time screen . 5 . If participant treat respiratory medication include inhaled bronchodilator , inhaled corticosteroid , systemic corticosteroid ( e.g . prednisone ≤ 10 mg/day equivalent ) , dose participant 's medication remain stable least 28 day prior screen . 6 . No clinically significant abnormality ( emphysema , bronchitis bronchiectasis ) detect via chest compute tomography ( CT ) chest Xray time screen . 7 . If female childbearing potential , participant must negative pregnancy test screen agree employ adequate birth control measure duration study . 8 . Participant willing able comply requirement protocol . 1 . Known ongoing history clinically significant pulmonary impairment COPD . 2 . The participant experience low respiratory infection ( LRTI ) /acute pulmonary exacerbation ( APE ) time enrollment ( sign Informed consent form ( ICF ) ) . Participant may rescreened clinical resolution LRTI/APE also remain stable least 4 week end LRTI/APE ) . 3 . Known ongoing history cor pulmonale . 4 . Known rest partial pressure carbon dioxide ( PaCO2 ) level &gt; 45 mmHg . 5 . Clinically significant congestive heart failure New York Heart Association ( NYHA ) Class III/IV symptom . 6 . The participant receive organ transplant , undergone major lung surgery , currently transplant list . 7 . Known history ongoing malignancy ( adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix ) . 8 . Smoker participant cease smoke less one year prior screen whose level cotinine outside normal range nonsmoker . All participant must agree refrain smoke throughout course study . 9 . The participant receive longterm therapy ( &gt; 28 day ) parenteral corticosteroid oral corticosteroid dos great 10 mg/day prednisone equivalent . 10 . The participant receive longterm roundtheclock oxygen supplementation ( temporary acute COPD exacerbation , supplemental oxygen ( O2 ) continuous positive airway pressure [ CPAP ] , bilevel positive airway pressure [ BiPAP ] ) . 11 . Participant contraindication CT 12 . Participant unwilling unable modify bronchodilator medication 6 hour short act β2 agonist , 24 hour longacting β2 agonist , 48 hour long act anticholinergic prior schedule quantitative CT scan . 13 . Known severe immunoglobulin A ( IgA ) deficiency ( ie , IgA level &lt; 8 mg/dL screen ) . 14 . Known history hypersensitivity follow infusion human blood blood component ( eg , human immunoglobulins human albumin ) . 15 . Presence clinically significant laboratory abnormality screen 16 . The participant clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol user , uncontrolled medical condition ( eg , unstable angina , transient ischemic attack , uncontrolled hypertension ) , opinion investigator , would affect participant 's safety compliance confound result study . 17 . Participant expose another IP within 28 day prior enrollment schedule participate another clinical study involve IP investigational device course study . 18 . Participant family member employee investigator . 19 . If female , participant pregnant nursing time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>